Nature Communications (Mar 2021)

Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy

  • Sara De Biasi,
  • Lara Gibellini,
  • Domenico Lo Tartaro,
  • Simone Puccio,
  • Claudio Rabacchi,
  • Emilia M. C. Mazza,
  • Jolanda Brummelman,
  • Brandon Williams,
  • Kelly Kaihara,
  • Mattia Forcato,
  • Silvio Bicciato,
  • Marcello Pinti,
  • Roberta Depenni,
  • Roberto Sabbatini,
  • Caterina Longo,
  • Massimo Dominici,
  • Giovanni Pellacani,
  • Enrico Lugli,
  • Andrea Cossarizza

DOI
https://doi.org/10.1038/s41467-021-21928-4
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 11

Abstract

Read online

Immune checkpoint inhibition (ICI) shows potential for cancer therapies, but response rates vary. Here, the authors use single-cell analyses to show that, in a 28 patient cohort, patients stratified by mucosal-associated invariant T (MAIT) percentages show different response rates, and ICI responders have more MAIT cells expressing CXCR4 and granzyme B.